Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclin-dependent kinase inhibitors.

Peter M Fischer1, Jane Endicott, Laurent Meijer

  • 1Cyclacel Limited, Dundee, DD1 5JJ, Scotland, U.K.

Progress in Cell Cycle Research
|November 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells.

Disease models & mechanisms·2026
Same author

Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.

Neuromolecular medicine·2026
Same author

Ciliogenesis associated kinase 1 accumulates in its inactive form during polycystic kidney disease progression.

bioRxiv : the preprint server for biology·2026
Same author

Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography.

ACS pharmacology & translational science·2026
Same author

Nitrogen-Doped Graphene Quantum Dots Conjugated to Leucettinib-21 Rescue Differentiating Zebrafish Purkinje Cells by Inhibiting Dyrk1A Kinase.

ACS applied nano materials·2026
Same author

DYRK1A and Parkinson's disease, facts and hypotheses.

Neurobiology of disease·2026

Cyclin-dependent kinases (CDKs) regulate vital cell functions. Numerous CDK inhibitors have been developed, but their varying selectivity requires further study for broader therapeutic applications.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) are crucial enzymes regulating fundamental cellular processes such as cell cycle control, apoptosis, and transcription.
  • CDKs play significant roles in neuronal physiology and cell differentiation.
  • Their involvement in diverse biological pathways highlights their importance in cellular function.

Purpose of the Study:

  • To review the current landscape of chemical inhibitors targeting CDKs.
  • To emphasize the need for further investigation into the kinase selectivity of these inhibitors.
  • To underscore the therapeutic potential of CDKs for a wider range of diseases.

Main Methods:

  • Extensive screening of chemical compounds.
  • Structure-based drug design utilizing CDK/inhibitor co-crystal structures.

Related Experiment Videos

  • Structure-activity relationship (SAR) studies.

    • Main Results:

    • Identification and characterization of a substantial number of chemical CDK inhibitors.
    • Demonstration that these inhibitors compete with ATP for binding to the kinase catalytic site.
    • Observation of significant variability in kinase selectivity among identified inhibitors.

    Conclusions:

    • CDK inhibitors represent a promising class of therapeutics.
    • Further research is essential to fully understand and exploit the selectivity profiles of CDK inhibitors.
    • CDKs are validated therapeutic targets for numerous diseases beyond their initially recognized roles.